Ceres Launches New Tool for Small to Medium-Sized Companies To Improve Their Sustainability Performance
About 67% of Cerevel Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Cerevel Therapeutics Holdings suggests that many traders are alarmed regarding Cerevel Therapeutics' prospects. The current market sentiment, together with Cerevel Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Cerevel Therapeutics stock news signals to limit their universe of possible portfolio assets.
Cerevel |
Ceres Launches New Tool for Small to Medium-Sized Companies To Improve Their Sustainability Performance
Read at kalkinemedia.com
 |
Cerevel Therapeutics Fundamental Analysis
We analyze Cerevel Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cerevel Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cerevel Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Cerevel Therapeutics is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Cerevel Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cerevel Therapeutics stock to make a market-neutral strategy. Peer analysis of Cerevel Therapeutics could also be used in its relative valuation, which is a method of valuing Cerevel Therapeutics by comparing valuation metrics with similar companies.
Peers
Cerevel Therapeutics Related Equities
| VTYX | Ventyx Biosciences | 8.97 | ||||
| SWTX | SpringWorks Therapeutics | 8.14 | ||||
| HOWL | Werewolf Therapeutics | 6.90 | ||||
| BPMC | Blueprint Medicines | 6.80 | ||||
| RNA | Avidity Biosciences | 5.36 | ||||
| RVMD | Revolution Medicines | 4.25 | ||||
| GPCR | Structure Therapeutics | 4.08 | ||||
| DSGN | Design Therapeutics | 3.85 | ||||
| TVTX | Travere Therapeutics | 3.68 | ||||
| IGMS | IGM Biosciences | 1.49 | ||||
| GLUE | Monte Rosa | 0.92 | ||||
| NUVL | Nuvalent | 0.09 | ||||
| CGEM | Cullinan Oncology | 1.39 | ||||
| STOK | Stoke Therapeutics | 1.75 | ||||
| TERN | Terns Pharmaceuticals | 1.86 | ||||
| IKNA | Ikena Oncology | 2.19 | ||||
| APLS | Apellis Pharmaceuticals | 3.27 | ||||
| DAWN | Day One | 4.03 | ||||
| MLYS | Mineralys Therapeutics, | 8.23 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Cerevel Stock
If you are still planning to invest in Cerevel Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cerevel Therapeutics' history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |